United Therapeutics ( UTHR) was among the best-performing health-related stocks Monday, with shares rising 10% after the biotechnology company posted third-quarter results that beat Wall Street forecasts. The company earned $15.8 million, or 61 cents a share, on sales of $33 million. Analysts polled by Thomson First Call expected earnings of 49 cents a share and sales of $32.4 million. Last year, United Therapeutics earned $6.3 million, or 27 cents a share, in the third quarter, on sales of $20 million. The company attributed the improved results to expanded sales of its drug Remodulin, which treats high blood pressure. Shares were trading up $6.38 to $73.48. Integra LifeSciences ( IART) fell 5% after the company posted mixed third-quarter results and forecast fourth-quarter sales below analysts' average expectation. The medical device maker reported earnings of $10.5 million, or 33 cents a share, for the third quarter. Excluding items, the company would have earned $11.5 million, or 36 cents a share, beating analysts' mean estimate by 2 cents a share. However, the company posted sales of $69.3 million, below Wall Street's forecast of $72.6 million. For the year-earlier period, Integra posted adjusted earnings of $8.6 million, or 26 cents a share, on sales of $59.1 million. For the fourth quarter, Integra forecast adjusted earnings, which exclude items, of 36 cents to 40 cents a share, compared with analysts' projection of 40 cents. The company sees sales of $71 million to $74 million, below analysts' expectation of $78.1 million. For 2006, the company continues to expect earnings of $1.65 to $1.75 a share. Sales, meanwhile, are expected to be between $330 million and $340 million. Analysts predict 2006 earnings of $1.67 a share and sales of $346.7 million. Integra shares were trading down $1.90 to $34.03. Shares of DaVita ( DVA) rose 3% after the company reported third-quarter earnings per share that beat expectations by a penny. The operator of dialysis centers earned $55.2 million, or 53 cents a share, on sales of $676.8 million. Analysts were expecting earnings of 52 cents a share and sales of $701.8 million. A year earlier, DaVita earned $60.4 million, or 59 cents a share, on sales of $595.5 million. Shares recently gained $1.32 to $49.31.